FDA Calendar September 2026: A Critical Look at Upcoming Approvals

The FDA calendar for September 2026 is packed with pivotal PDUFA dates that could alter treatment landscapes. We're tracking six key drugs with critical approval dates this month. Our analysis will center on their potential impact and market dynamics, especially given the heightened investor interest around these upcoming FDA approvals.

The full September 2026 PDUFA calendar

Zidesamtinib: A New Option for ROS1-Positive NSCLC

Zidesamtinib, developed by Nuvectis Pharma (ticker: NUVL), has a PDUFA date set for September 18, 2026. This drug targets adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have received at least one prior ROS1 TKI. The urgency for this treatment comes from the limited options available for this specific patient group. Currently, the market is crowded with various therapies, yet ROS1-positive NSCLC remains difficult to treat effectively. While the PoA isn't available, the upcoming decision could significantly affect Nuvectis's valuation. The risk lies in whether Zidesamtinib can show a clear advantage over existing therapies, crucial for its commercial success.

Ameluz®PDT: A Promising Therapy for Basal Cell Carcinoma

Biofrontera Inc. (ticker: BFRI) is awaiting a PDUFA decision for Ameluz®PDT on September 28, 2026. This therapy is designed for superficial basal cell carcinoma (sBCC) and has shown a strong efficacy profile, with a 65.5% clearance rate in pivotal trials versus 4.8% for placebo. It works by converting 10% aminolevulinic acid (ALA) gel to protoporphyrin IX, which, upon red-light activation, generates cytotoxic reactive oxygen species to selectively destroy sBCC lesions. With the global market for sBCC treatments projected at $1.2 billion, Ameluz®PDT's potential is substantial, offering a non-invasive alternative to surgery. Risks include pending long-term recurrence data due in December 2025 and competition from emerging non-surgical therapies.

OST-HER2: A Novel Approach to Osteosarcoma

OST-HER2, from OncoSec Medical (ticker: OSTX), is up for a BLA submission review on September 30, 2026. This drug aims to prevent or delay recurrent, fully resected pulmonary metastatic osteosarcoma. With an 11.2% run-up, investor interest is clear. The indication addresses a significant unmet need, as osteosarcoma can be aggressive and challenging to manage post-surgery. OST-HER2's efficacy will depend on its ability to show a marked improvement over current treatments. The risk is that clinical data may not support this, which could lead to a disappointing market response if the FDA decides against approval.

Upcoming PDUFA Dates: What Investors Should Watch

Besides the three highlighted drugs, several other PDUFA dates are approaching this month. Zilurgisertib (ticker: MIRM) is under review for fibrodysplasia ossificans progressiva (FOP) with a PDUFA date on September 26, 2026. Apitegromab (ticker: SRRK) aims to treat spinal muscular atrophy (SMA), with a decision expected on September 30, 2026. Each of these drugs holds promise, particularly given their high PoA bands. Investors should closely watch these dates and the potential implications of the FDA's decisions. The risk is the market's reaction to any surprises, especially if a drug faces a Complete Response Letter (CRL).

Market Dynamics: The Influence of FDA Decisions

The FDA's upcoming decisions can send ripples through the biotech market. A favorable decision for Ameluz®PDT could validate non-surgical treatment pathways and potentially reshape market dynamics for sBCC therapies. Conversely, a rejection could severely dent investor confidence, especially for companies like Biofrontera, which depend heavily on their market offerings. The interplay between approval decisions and market sentiment is crucial, particularly in a sector prone to volatility. As we near these PDUFA dates, the stakes are high, with investor sentiment likely to fluctuate based on the anticipated outcomes.

Investor Strategies: Navigating the Upcoming FDA Calendar

Given the numerous catalysts in the FDA calendar for September 2026, investors need to strategize carefully. The decisions on Zidesamtinib, Ameluz®PDT, and OST-HER2 present both opportunities and risks. Investors should consider diversifying their exposure to these names while focusing on the underlying fundamentals. Understanding the clinical trial data backing each drug can offer insights into their probability of approval, crucial for informed investment choices. Monitoring insider activity and options positioning can reveal market sentiment leading up to these critical dates. Significant price movements following FDA decisions call for a proactive approach.

The bottom line

September 2026's FDA calendar presents various opportunities and risks for biotech investors. Monitoring these developments will be essential for navigating this dynamic landscape.